Proteolysis targeting chimeric pharmaceutical
AssigneesCalifornia Institute of Technology, Yale School of Medicine, The Regents of the University of California
InventorsRaymond J. Deshaies, Craig Crews, Kathleen M. Sakamoto
Life of this patent
Estimating the term…
Abstract
The present invention is based on the discovery of a composition that provides targeted ubiquitination. Specifically the composition contains an ubiquitin pathway protein binding moiety which recognizes an ubiquitin pathway protein and a targeting moiety which recognizes a target protein. In addition, the present invention provides libraries of compositions, where each composition contains an ubiquitin pathway protein binding moiety and a member of a molecular library. The libraries of the present invention can be used to identify proteins involved in a predetermined function of cells.
Claims4
A composition comprising:
- a) a ubiquitin pathway protein binding moiety, wherein the ubiquitin pathway binding moiety is IkB-alpha or an IkB-alpha peptide;
- and
- b) a target protein binding moiety covalently coupled to the ubiquitin pathway protein moiety of a), wherein the target protein binding moiety is ovalicin.
Dependencies are inferred from the claim text.